Secondly, EGFR-mutated adenocarcinomas were weakly associated with higher fractions of total LOH compared with KRAS-mutated and EGFRwt/KRASwt tumors both overall and in stage I disease (p=0.05, ANOVA), but not in tumors of higher stages (≥II), or tumors stratified by gender. The gene discussed is KRAS; the disease is adenocarcinoma.